Management Team

Bruce Montgomery, MD  
Chief Executive Officer

Mark Surber, PhD  
Chief Scientific Officer

Nancy McKinley  
Vice President, Finance

Kelly Otto, MS  
Vice President, Clinical Development Operations

Stephen Pham, PhD  
Vice President, Product Development

Board of Directors

Bruce Montgomery, MD  
Chief Executive Officer

Jonathan Leff, MD  
Independent

Ketan Patel, MD  
F-Prime Capital

Sofia Ioannidou, PhD  
Andera Partners

Tiba Aynechi, PhD  
Novo A/S

Niall O’Donnell, PhD  
RiverVest Venture Partners

Heather Preston, MD  
Pivotal bioVenture Partners

Robert Mittendorff, MD  
Norwest Venture Partners

Mark Surber, PhD  
Chief Scientific Officer, Observer

Contact Us

Avalyn Pharma  
701 Pike Street Ste. 1500  
Seattle, WA 98101  
info@avalynpharma.com

About Avalyn

Avalyn is dedicated to improving the care and outcomes of people with severe respiratory diseases by developing novel inhaled therapeutics that address significant unmet clinical needs.

Our lead asset is inhaled pirfenidone (AP01) for the treatment of idiopathic pulmonary fibrosis (IPF). As an orphan-designated product, AP01 offers the potential to show superior efficacy and safety to Roche/Genentech’s oral pirfenidone (Esbriet®), a product selling $1Bn annually despite a limited therapeutic margin.

The company is backed by leading life science investors F-Prime Capital, Andera Partners, Novo A/S, RiverVest Venture Partners, Pivotal and Norwest. With offices in Seattle and San Diego, Avalyn’s experienced IPF and inhaled product development team is advancing AP01 through proof-of-concept for IPF and additional pipeline candidates for IPF and other severe respiratory diseases.

Therapeutic Focus

Although two products are available to treat IPF, both are poorly tolerated and only slow disease progression; neither is a cure.

IPF is a fatal lung disease characterized by progressive scarring, reduced exercise capacity and death due to respiratory failure or co-morbidities. With a 2-5 year survival period, IPF has more deaths per year than breast cancer and only lung cancer has a worse prognosis. Recently, the first drugs were approved for IPF treatment; oral pirfenidone (Esbriet®) and oral nintedanib (Ofev®). While these medicines are an important first step to treat IPF, a substantial unmet need remains for highly compliant medicines enabling improved efficacy and compliance as stand-alone and add-on combination therapies.

AP01 (Pirfenidone Solution for Inhalation)

Pirfenidone is a low potency drug that requires a very large oral dose to deliver effective lung levels. Unfortunately, blood-level safety limits and poor compliance due to oral dose-related adverse effects reduce the oral product’s benefit. To maximize pirfenidone’s potential, Avalyn has reformulated pirfenidone for nebulization and inhaled aerosol lung delivery. By this approach, small inhaled doses delivered directly to the lung hold promise to maximize pirfenidone’s effect while avoiding adverse effects associated with oral delivery. Our data indicates that as stand-alone therapy, inhalation may substantially-reduce or eliminate oral adverse effects and may increase pirfenidone’s efficacy through a greater lung dose and improved compliance. Moreover, as a safe and well-tolerated therapy, AP01 may enable pirfenidone’s use in combination regimens (e.g., with Ofev®) without increasing total adverse events.